Stockreport

Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks

Pharvaris N.V. - Ordinary Shares  (PHVS) 
PDF Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (pAll secondary efficacy endpoints met (p1 (medi [Read more]